Alchemia Ltd (ACL)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Alchemia Ltd (ACL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013540
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:27
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Alchemia Ltd (Alchemia) is a biopharmaceutical company that focuses on the discovery and development of drugs for the treatment of cancer and respiratory disorders. It sold the worldwide exclusive intellectual property rights to its product, Fondaparinux sodium (a generic version of the anticoagulant drug Arixtra, approved in the US and Europe for the treatment of deep vein thrombosis and pulmonary embolism), to Dr. Reddy’s Laboratories. The company is developing a late stage cancer product pipeline derived from the HyACT platform, and has a proprietary drug discovery platform, VAST, derived from its chemistry expertise. Alchemia is headquartered in South Melbourne, Victoria, Australia.

Alchemia Ltd (ACL) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alchemia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Alchemia Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alchemia Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Alchemia Enters Into Collaboration Agreement with Merck Serono 11
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 12
Licensing Agreements 13
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 13
Equity Offering 14
Alchemia Completes Rights Offering Of Shares For US$2.8 Million 14
Alchemia Completes Private Placement Of Shares For US$10.4 Million 15
Alchemia Completes Rights Issue Of Shares For US$5.4 Million 16
Alchemia Completes First Tranche Of Private Placement Of Shares For US$7.2 Million 18
Asset Transactions 19
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 19
Acquisition 20
Panther Biotech to Acquire Alchemia Oncology 20
Alchemia Ltd – Key Competitors 21
Alchemia Ltd – Key Employees 22
Alchemia Ltd – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Corporate Communications 24
Jun 29, 2016: Alchemia Announces Resignation of Non-Executive Director 24
Mar 07, 2016: Alchemia Announces Appointment of Non – Executive Director 25
Feb 29, 2016: Alchemia Announces Appointment of Non – Executive Chairman and Retirement of Non – Executive Chairman 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Alchemia Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Alchemia Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Alchemia Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Alchemia Ltd, Medical Devices Deals, 2011 to YTD 2017 9
Alchemia Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Alchemia Enters Into Collaboration Agreement with Merck Serono 11
Alchemia Enters Into Drug Discovery Agreement With AstraZeneca 12
Alchemia Enters Into Licensing Agreement With Cancer Research Technology For FAK Inhibitors 13
Alchemia Completes Rights Offering Of Shares For US$2.8 Million 14
Alchemia Completes Private Placement Of Shares For US$10.4 Million 15
Alchemia Completes Rights Issue Of Shares For US$5.4 Million 16
Alchemia Completes First Tranche Of Private Placement Of Shares For US$7.2 Million 18
Dr. Reddy’s Lab Acquires Intellectual Property Rights of Fondaparinux Sodium from Alchemia for USD17.5 Million 19
Panther Biotech to Acquire Alchemia Oncology 20
Alchemia Ltd, Key Competitors 21
Alchemia Ltd, Key Employees 22
Alchemia Ltd, Subsidiaries 23

★海外企業調査レポート[Alchemia Ltd (ACL)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Uranium One Inc:企業の戦略的SWOT分析
    Uranium One Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • PsychoGenics Inc-製薬・医療分野:企業M&A・提携分析
    Summary PsychoGenics Inc (PsychoGenics) is an preclinical contract research organization that offers contract research, standard and customized preclinical services and drug discovery services. The organization offers various behavioral tests to drug candidates in the areas of pain and inflammation, …
  • F&C Investment Trust PLC:企業の戦略・SWOT・財務分析
    F&C Investment Trust PLC - Strategy, SWOT and Corporate Finance Report Summary F&C Investment Trust PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Jardine Matheson Holdings Ltd:企業の戦略・SWOT・財務分析
    Jardine Matheson Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Jardine Matheson Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • QuickLogic Corporation (QUIK):企業の財務・戦略的SWOT分析
    QuickLogic Corporation (QUIK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Saft Groupe SA:企業の戦略的SWOT分析
    Saft Groupe SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Avalara Inc:企業のM&A・事業提携・投資動向
    Avalara Inc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Avalara Inc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Metropolitan Health Networks Inc-製薬・医療分野:企業M&A・提携分析
    Summary Metropolitan Health Networks Inc (MHN) a subsidiary of Humana Inc is a healthcare organization that offers primary care services. The organization operates through a network of doctors, nurses and specialists for seniors insured through Medicare. It provides service through provider service …
  • DecImmune Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary DecImmune Therapeutics Inc (DecImmune) is a pharmaceutical research company. The company develops a humanised antibody, which is used in preventing tissue damage and block inflammation caused from vascular injuries. It conducts research and development on N2, an innate IgM-mediated auto-immu …
  • ProteinSimple-医療機器分野:企業M&A・提携分析
    Summary ProteinSimple, formerly Cell Biosciences Inc, a subsidiary of Bio Techne Corp, is a medical device company that offers protein analysis solutions. The company offers products such as simple plex systems, simple western systems, micro-flow imaging systems, cIEF and CE-SDS; gel documentation s …
  • Outokumpu Oyj:企業のM&A・事業提携・投資動向
    Outokumpu Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Outokumpu Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Siltech Corp:企業の戦略的SWOT分析
    Siltech Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • AltheaDx Inc-医療機器分野:企業M&A・提携分析
    Summary AltheaDx Inc (AltheaDx) is a biotechnology company that offers molecular diagnostic services. The company provides tests such as cardiovascular tests, pain tests, thrombophilia tests and psychiatric tests. It provides diagnostic development, clinical trial and discovery services. AltheaDx’ s …
  • Strike Resources Ltd (SRK):企業の財務・戦略的SWOT分析
    Summary Strike Resources Ltd (Strike Resources) is a mining and mineral exploration and development company. The company explores for uranium, coal, and iron ore. Strike Resources’ projects portfolio includes Cusco Iron Ore project, Burke Graphite Project, Solaroz Lithium Brine Project, Pilbara Lith …
  • SeraCare Life Sciences Inc:企業の戦略的SWOT分析
    SeraCare Life Sciences Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Prologis, Inc.:企業の戦略・SWOT・財務情報
    Prologis, Inc. - Strategy, SWOT and Corporate Finance Report Summary Prologis, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • MSIG Insurance (Singapore) Pte. Ltd.:企業の戦略・SWOT・財務情報
    MSIG Insurance (Singapore) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report Summary MSIG Insurance (Singapore) Pte. Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Bain & Company, Inc.:企業の戦略・SWOT・財務分析
    Bain & Company, Inc. - Strategy, SWOT and Corporate Finance Report Summary Bain & Company, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Beijer Ref Ab:企業のM&A・事業提携・投資動向
    Beijer Ref Ab - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Beijer Ref Ab Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments …
  • Amryt Pharma plc (AMYT):製薬・医療:M&Aディール及び事業提携情報
    Summary Amryt Pharma plc (Amryt) is a specialty pharmaceutical company that develops, manufactures and commercializes novel treatments for patients with rare and orphan diseases. It has two marketed products include Lojuxta for the treatment of adult HoFH and Episalvan for the treatment of PTW. The …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆